Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10190Neoplasms 7819Carcinoma, Non-Small-Cell Lung 5763Prostatic Neoplasms 5032Colorectal Neoplasms 4608Lung Neoplasms 3727Leukemia, Myeloid, Acute 3104Neoplasm Metastasis 3086Multiple Myeloma 3083Pancreatic Neoplasms 2846Melanoma 2654Ovarian Neoplasms 2578Lymphoma 2571Carcinoma, Hepatocellular 2483Stomach Neoplasms 2331Recurrence 2229Head and Neck Neoplasms 2106Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1906Glioblastoma 1799Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1695Lymphoma, Follicular 1655Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Large B-Cell, Diffuse 1598Carcinoma, Renal Cell 1579

Interventions

Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vitamin D3 × Clear all
NCT03389659 2018-01-03

XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown
750 enrolled

Vitamin D3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡